Cite
HARVARD Citation
Quixabeira, D. et al. (n.d.). 50P Enhancing TIL and NK cells adoptive therapies with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer. Immuno-oncology technology. p. . [Online].